Oncolytics secures new U.S. patent for pelareorep manufacturing through 2044; method-of-use app to 2046

ONCOLYTICS BIOTECH INC

USPTO issued patent covering pelareorep manufacturing process, expected protection into 2044.
Previously filed method-of-use patent application under review, if issued would protect into 2046.
Company plans additional patent filings in 2026 to expand IP across therapeutic applications and combinations.
CEO states patent supports commercial-scale production and long-term value of pelareorep.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.